Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome

Authors	LEMSTROVA Radmila BRYNYCHOVA Veronika HUGHES David J. HLAVAS Viktor DVORAK Pavel DOHERTY Joanne E. MURRAY Helena A. CROCKARD Martin OLIVERIUS martin HLAVSA Jan HONSOVA Eva MAZANEC Jan KALA Zdeněk LOVECEK Martin HAVLIK Roman EHRMANN Jiri STROUHAL Ondrej SOUCEK Pavel MELICHAR Bohuslav MOHELNIKOVA-DUCHONOVA Beatrice
Year of publication	2017
Type	Article in Periodical
Magazine / Source	Oncology Letters
MU Faculty or unit	Faculty of Medicine
Citation
Doi	http://dx.doi.org/10.3892/ol.2017.6946
Field	Surgery incl. transplantology
Keywords	pancreatic ductal adenocarcinoma; KRAS; gene expression; mutation; overall survival
Description	Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, and no targeted therapy is currently available. The aim of the present study was to investigate the prognostic significance of the expression of V-Ki-ras2 kirsten rat sarcoma viral oncogene homolog (KRAS), downstream signaling pathway genes and the association with clinical characteristics in PDAC patients undergoing radical surgery. Tumors and adjacent non-neoplastic pancreatic tissues were examined in 45 patients with histologically verified PDAC. KRAS and B-Raf proto-oncogene, serine/threonine kinase (BRAF) gene mutation analysis was performed using the KRAS/BRAF/phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha array.